Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 12/20 | 0.68 |
| ▸ | EML4 | Q9HC35 | 11/20 | 0.68 |
| ▸ | FLT3 | P36888 | 9/20 | 0.68 |
| ▸ | RET | P07949 | 8/20 | 0.68 |
| ▸ | ROS1 | P08922 | 8/20 | 0.68 |
| ▸ | BTK | Q06187 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 2/20 | 0.53 |
| ▸ | ETV6 | P41212 | 2/20 | 0.53 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | BUB1 | O43683 | 1/20 | 0.53 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.53 |
| ▸ | STK16 | O75716 | 1/20 | 0.53 |
| ▸ | STK10 | O94804 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16206833 | 0.92 | EML4 (0.63) | ALKEML4FLT3RETROS1 | |
| SCHEMBL16207084 | 0.89 | FLT3 (0.70) | ALKEML4FLT3RETROS1 | |
| SCHEMBL16206832 | 0.83 | EML4 (0.56) | ALKEML4FLT3RETROS1 | |
| SCHEMBL10129884 | 0.83 | EML4 (0.74) | ALKEML4FLT3RETROS1 | |
| SCHEMBL16206853 | 0.82 | EML4 (0.74) | ALKEML4FLT3RETROS1 | |
| SCHEMBL10156947 | 0.81 | FLT3 (0.74) | ALKEML4FLT3RETROS1 | |
| SCHEMBL282851 | 0.81 | EML4 (1.00) | ALKEML4FLT3RETROS1 | |
| SCHEMBL16207078 | 0.81 | EML4 (0.65) | ALKEML4FLT3RETROS1 | |
| SCHEMBL10129894 | 0.80 | EML4 (0.77) | ALKEML4FLT3RETROS1 | |
| SCHEMBL16206829 | 0.79 | EML4 (0.71) | ALKEML4FLT3RETROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805940-B1 | PYRAZINE CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| EP-2805940-A1 | PYRAZINE CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | EGFR, ERBB2, ALK | ALK 3/4885EML4 158/4885FLT3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.